Neuronal ceroid lipofuscinoses

Neuronal ceroid lipofuscinoses, or NCLs, are a group of rare inherited conditions that damage nerve cells over time. They mainly affect the brain, nervous system, and eyes.

NCLs are sometimes called Batten disease. Historically, that name referred to a juvenile form, but it is now often used for the whole group.

There are several NCL types, named after the affected gene, such as CLN1, CLN2, and CLN3. The genetic type influences the age when symptoms begin, which symptoms appear, and how quickly they progress. Symptoms can start in infancy, childhood, adolescence, or adulthood.

Most NCLs affect structures inside cells called lysosomes. Lysosomes break down and recycle unwanted material. When certain lysosomal proteins do not work properly, waste-like substances build up in cells. Nerve cells are especially vulnerable, although the exact way this buildup causes damage is complex.

NCLs matter because they are progressive. This means symptoms and disability usually increase over time. There is no cure, but treatment can control symptoms, preserve comfort and independence, and support the person and family. A specific enzyme-replacement treatment can slow part of the decline caused by CLN2.

Symptoms differ between NCL types. Even people with changes in the same gene may not have exactly the same course.

In children, an early sign may be losing skills that had already developed. This is called developmental regression. A child might become less steady, have difficulty speaking, or need more help with everyday tasks.

Common symptoms include:

• Seizures
• Worsening vision or blindness
• Problems with balance, walking, and coordination
• Muscle stiffness, spasms, or involuntary movements
• Declining memory, learning, language, or problem-solving skills
• Changes in mood, sleep, or behaviour
• Difficulty speaking or swallowing

Some infants develop symptoms before they have gained many movement or communication skills. Juvenile forms may first cause vision loss, school difficulties, or seizures. Adult-onset forms may cause seizures, movement problems, or changes in thinking and behaviour; significant vision loss is not present in every adult form.

Seizures can take different forms. Some cause shaking and loss of awareness. Others cause brief staring, sudden muscle jerks, or unexpected falls.

As an NCL progresses, walking, communication, eating, and personal care may become harder. The timing and order of these changes cannot be predicted from the condition’s name alone.

NCLs are caused by harmful changes, called pathogenic variants, in genes involved in cell function. These genes are commonly given CLN names.

Most NCLs are inherited in an autosomal recessive pattern. This means a person has an altered copy of the gene from each parent. The parents are usually healthy carriers because they have one working copy and one altered copy.

Some adult-onset NCLs, including CLN4, are inherited in an autosomal dominant pattern. In these forms, one altered gene copy can cause the condition.

The main risk factor is having a relevant genetic change in the family. NCLs are not caused by parenting, diet, an infection, or anything someone did during pregnancy. They are not contagious.

A person can be the first in a family to receive the diagnosis. Recessive gene changes can pass silently through several generations, so there may be no known family history.

Diagnosis often begins with a neurological assessment. This reviews seizures, movement, development, thinking, behaviour, and vision. An eye examination may find changes in the retina, the light-sensitive layer at the back of the eye.

Genetic testing usually confirms an NCL. A blood or saliva sample may be tested with a panel that looks at several genes linked to epilepsy, developmental regression, vision loss, or NCL. Broader testing, such as exome or genome sequencing, may be used when the first tests do not find a cause.

For some types, enzyme tests can show that a particular lysosomal enzyme is missing or has very low activity. These tests are especially useful for CLN1 and CLN2. Genetic testing is still important because it identifies the specific gene changes and can help with family testing.

Other tests may include:

• An electroencephalogram, or EEG, to measure the brain’s electrical activity
• MRI scans to look for changes in the brain
• Tests of retinal and visual function
• Swallowing, movement, speech, and developmental assessments

These tests help show how the condition is affecting someone, but an MRI or EEG alone cannot confirm the genetic type. A tissue biopsy is now needed less often because genetic and enzyme testing are more widely available.

There is no treatment that cures all NCLs. Care is usually coordinated through a specialist neurological or metabolic team and adjusted as needs change.

Cerliponase alfa is an enzyme-replacement treatment for CLN2. It replaces the enzyme that is missing in this type and can slow loss of walking ability. It does not reverse damage that has already occurred or treat other NCL types.

Cerliponase alfa is delivered into fluid around the brain through an implanted access device. Treatment requires regular specialist visits and monitoring for problems such as infection, device complications, or infusion reactions. Eligibility and approved use differ by age and country.

Other care focuses on symptoms and everyday function. It may include:

• Anti-seizure medicines selected for the person’s seizure pattern
• Medicines or physical care for stiffness, spasms, pain, or involuntary movements
• Physiotherapy and equipment to support posture and mobility
• Occupational therapy for daily activities and home adaptations
• Speech therapy and communication devices
• Vision support and education adapted for sight loss
• Sleep and behavioural support
• Swallowing assessment and nutrition support

If swallowing becomes unsafe or eating takes too much energy, changes in food texture may help. Some people eventually use a feeding tube to provide nutrition, fluids, and medicines. This decision should reflect the person’s needs, comfort, and family goals.

Palliative care can be involved from an early stage. It is not limited to end-of-life care. It can help manage symptoms, plan ahead, arrange practical support, and protect quality of life alongside other treatments.

NCLs can affect many parts of daily life as nerve-cell damage progresses. Possible complications include falls, injuries, loss of mobility, joint stiffness, and pressure injuries from spending long periods in one position.

Swallowing problems may lead to weight loss, dehydration, or food entering the airway. This is called aspiration and can cause a chest infection.

Seizures may become more frequent or difficult to control. A prolonged seizure can develop into status epilepticus, which is a medical emergency.

Communication may become limited, but this does not mean the person has no awareness, preferences, or emotional needs. Families and care teams may need to rely on facial expression, movement, sounds, or communication technology.

Some NCL types shorten life expectancy, particularly forms that begin early and progress quickly. The outlook is different for later-onset forms, and an individual timeline is often uncertain.

NCLs cannot be prevented in someone who has inherited the gene changes that cause them. Lifestyle changes do not stop an NCL from developing.

After a genetic cause has been identified, relatives may choose carrier or predictive genetic testing. A genetic counsellor can explain inheritance, the limits of testing, and what results could mean for other family members.

People planning a pregnancy may wish to discuss reproductive options. Depending on the known gene changes and local services, these can include testing during pregnancy or testing embryos created through in vitro fertilisation. These are personal choices rather than treatments or guarantees.

NCLs usually progress over months and years, but the pace differs greatly by genetic type and age at onset. Earlier-onset forms often progress more quickly than forms beginning in adolescence or adulthood. The exact course cannot always be predicted, even after genetic confirmation.

Skills that have been lost because of nerve-cell damage do not usually return. Treatment may slow certain changes, reduce symptoms, or help someone use their remaining abilities for longer. Progress is often uneven: a person may seem stable for a period and then need more support.

Regular follow-up commonly reviews seizures, vision, movement, swallowing, nutrition, sleep, communication, pain, and equipment needs. These are routine appointments unless a sudden or severe problem develops.

Children may need an individual education plan, accessible learning materials, and support for visual impairment. Adults may need changes at work, help with transport, or increasing assistance at home. Mobility aids and communication devices can support participation rather than signal that therapy has failed.

NCL also affects parents, siblings, partners, and other caregivers. Respite care, social services, mental health support, and condition-specific family organisations can reduce isolation and help with long-term planning.

Arrange a routine or prompt medical review if there are new seizures, worsening vision, repeated falls, loss of skills, increased stiffness, or changes in behaviour or sleep. Coughing during meals, weight loss, long mealtimes, or frequent chest infections should lead to a swallowing and nutrition review.

Contact the specialist team promptly for redness, swelling, leakage, fever, unusual sleepiness, or pain around an implanted treatment device. These may indicate infection or another device problem.

Seek emergency help for:

• A seizure lasting five minutes or longer, unless the emergency plan says otherwise
• Repeated seizures without recovery between them
• A first seizure
• Severe breathing difficulty, blue or grey lips, or choking that does not clear
• Sudden unresponsiveness or a serious injury
• Signs of a severe treatment reaction, such as breathing difficulty or facial swelling

Follow any personalised seizure or emergency plan provided by the clinical team.

Is NCL the same as Batten disease?

Batten disease is commonly used as another name for the NCL group. Older sources may use it mainly for juvenile-onset NCL, especially CLN3.

Is NCL always diagnosed in childhood?

No. Many types begin in infancy or childhood, but some first cause symptoms during adolescence or adulthood. Adult forms may be mistaken for other seizure, movement, or cognitive conditions before genetic testing identifies the cause.

Can someone with NCL pass it to their children?

They may pass on the altered gene. The chance that a child develops an NCL depends on the genetic type and the other parent’s genes. Genetic counselling can calculate the possibilities after the family’s specific gene changes are known.

Can NCL be cured with gene therapy?

No approved gene therapy currently cures the NCL group. Gene-based treatments are being studied for some types, but research participation does not guarantee benefit and may involve significant burdens or risks.

Does treatment stop CLN2 from progressing?

Cerliponase alfa can slow loss of walking ability in CLN2, but it does not stop every part of the condition or restore skills already lost. Ongoing symptom treatment and supportive care are still needed.

Can a person with NCL still communicate after losing speech?

Often, yes. Eye movements, facial expressions, sounds, gestures, switches, and communication devices may help. Communication methods usually need to change as vision and movement change.